Vitamin B12, Vitamin B6, Zinc, Riboflavin and Folic Acid: study protocols
5 study groups took Vitamin B12 together with Vitamin B6, Zinc, Riboflavin and Folic Acid. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Vitamin B12
5 study groups in 5 studies say how much Vitamin B12 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 2.5 mcg to 5 mcg, 60% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 1 mcg or less | 1 |
| 1 mcg to 2.5 mcg | 0 |
| 2.5 mcg to 5 mcg | 3 |
| 5 mcg to 10 mcg | 1 |
Dose per serving from research: Vitamin B6
5 study groups in 5 studies say how much Vitamin B6 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg and 2.5 mg to 5 mg, 40% of 5 study groups each.
| Daily dose | Study groups |
|---|---|
| 500 mcg or less | 1 |
| 500 mcg to 1 mg | 0 |
| 1 mg to 2.5 mg | 2 |
| 2.5 mg to 5 mg | 2 |
Dose per serving from research: Zinc
5 study groups in 5 studies say how much Zinc participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg to 10 mg and 10 mg to 25 mg, 40% of 5 study groups each.
| Daily dose | Study groups |
|---|---|
| 5 mg to 10 mg | 2 |
| 10 mg to 25 mg | 2 |
| 25 mg to 50 mg | 1 |
Dose per serving from research: Riboflavin
5 study groups in 5 studies say how much Riboflavin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg, 80% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 500 mcg or less | 1 |
| 500 mcg to 1 mg | 0 |
| 1 mg to 2.5 mg | 4 |
Dose per serving from research: Folic Acid
5 study groups in 5 studies say how much Folic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mcg to 500 mcg, 80% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mcg to 250 mcg | 1 |
| 250 mcg to 500 mcg | 4 |
Commonly used together
5 of 5 study groups took Vitamin B12, Vitamin B6, Zinc, Riboflavin and Folic Acid with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Iron | 4 |
| Copper | 3 |
| Iodine | 3 |
| Niacin | 3 |
| Thiamine | 3 |
| Vitamin A | 3 |
| Vitamin D | 3 |
| Vitamin E | 3 |
5 study groups
| Study | |||||||
|---|---|---|---|---|---|---|---|
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 2.6 mcg | 2.2 mg | 30 mg | 1.8 mg | 400 mcg | — | — |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 5.2 mcg | 2.6 mg | 10 mg | 1.8 mg | 400 mcg | — | 870 |
| Daily supplementation of a multiple micronutrient powder improves folate but not thiamine, riboflavin, or vitamin B(12) status among young Laotian children: a randomized controlled trial 2022 · micronutrient powder group (MNP) · Children aged 6–23 months in rural Lao PDR; no disease-based selection, with high prevalence of undernutrition and micronutrient deficiencies | 0.9 mcg | 500 mcg | 10 mg | 500 mcg | 150 mcg | 36 weeks | 130 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · UNIMMAP tablet · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 2.6 mcg | 1.9 mg | 15 mg | 1.4 mg | 400 mcg | 12 weeks | 105 |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Normocis 400® group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 5 mcg | 3 mg | 12.5 mg | 2.4 mg | 400 mcg | 60 days | 52 |